Company / Return on Assets (ROA)
ALNYLAM PHARMACEUTICALS, INC. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-0.4%
FY2025
5-year range
-24.3% / -0.4%
FY2021-FY2025
Trend
+94.4%
vs FY2024
Sector context
#61 of 213
Health Care
What the data says
At -0.4%, ALNYLAM PHARMACEUTICALS, INC.'s return on assets (roa) ranks #61 of 213 in the Health Care sector. Return on Assets (ROA) has increased for 4 consecutive years, from -24.3% in FY2021 to -0.4% in FY2025.
Based on SEC 10-K filings.
-0.4% in FY2025 with a 5-year CAGR of +22.0%.
Improved from -11.5% to -0.4% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +23.8pp
- 5-Year Change
- +22.0pp
- 10-Year Change
- -
Sector benchmark
#61 of 213 in Health CareTop 29% of 213This company -0.4% Sector average -24.2%
▼
+98.5% above sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s return on assets (roa) has grown for 4 consecutive years.
- In FY2025, return on assets (roa) increased 94.4% year-over-year.
- Currently 23.8pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -0.4% | +94.4% |
| FY2024 | -6.6% | +42.9% |
| FY2023 | -11.5% | +52.5% |
| FY2022 | -24.2% | +0.5% |
| FY2021 | -24.3% | -8.8% |
| FY2020 | -22.4% | -9.1% |
| FY2019 | -20.5% | +21.3% |
| FY2018 | -26.0% | -5.8% |
| FY2017 | -24.6% | +24.2% |
| FY2016 | -32.5% | -55.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026